Cian Healthcare
4.90
-0.09(-1.80%)
Market Cap₹12.27 Cr
PE Ratio-0.48
IndustryHealthcare
Company Performance:
1D-1.80%
1M-7.55%
6M+25.00%
1Y+49.85%
5Y-61.72%
View Company Insightsright
More news about Cian Healthcare
18Nov 25
Cian Healthcare's Audited Results Marred by Disclaimer of Opinion Amid CIRP Challenges
Cian Healthcare's auditors, M/s. S S R C A & Co., have issued a disclaimer of opinion on the company's FY2025 consolidated financial statements. The disclaimer cites insufficient evidence due to ongoing Corporate Insolvency Resolution Process (CIRP) affecting both Cian Healthcare and its subsidiary, Dr. Smiths Biotech Private Limited. Auditors highlighted issues including incomplete records, unverified inventory valuations, and missing documentation. The CIRP has led to delays in finalizing and filing the audited consolidated financial statements. Management, represented by Resolution Professional Roshen Chordiya, has committed to keeping stakeholders informed and ensuring compliance with regulatory timelines.
07Nov 25
Cian Healthcare's Resolution Plan Reserved for Order by Mumbai NCLT
The National Company Law Tribunal (NCLT) Mumbai Bench has reserved the resolution plan application for Cian Healthcare Limited (CHCL) submitted by Mr. Pradeep Kumar Jain for orders. This development occurred on November 6, 2025, marking a crucial step in CHCL's corporate insolvency resolution process. The resolution plan was previously approved by the Committee of Creditors and submitted to NCLT on October 7, 2025. CHCL has committed to providing detailed disclosure upon receipt of the written order, including information on treatment of existing securities, changes to shareholding pattern, and other material disclosures under the approved plan.
17Oct 25
Cian Healthcare's Committee of Creditors Approves Resolution Plan Modifications
Cian Healthcare held its 15th Committee of Creditors meeting on October 17, 2025, as part of its Corporate Insolvency Resolution Process. The committee approved modifications to the resolution plan submitted by Mr. Pradeep Kumar Jain, including amendments to accounting treatment and revisions to reliefs and concessions. The next NCLT hearing for plan approval is scheduled for November 6, 2025.
18Sept 25
Cian Healthcare's Resolution Professional Re-appoints Cost Auditor Amid CIRP
Cian Healthcare Limited, currently under Corporate Insolvency Resolution Process (CIRP), has re-appointed M/s Suraj Lahoti & Associates as its Cost Auditor for FY 2025-2026. The appointment was made by Resolution Professional, Mr. Roshen Chordiya, on September 18, 2025. The company's CIRP was restored following an NCLT order dated August 14, 2024. M/s Suraj Lahoti & Associates brings over 8 years of experience in cost audit and related services across various industries.
06Sept 25
Cian Healthcare Appoints DMKH & Co. as Transaction Auditor Amid Insolvency Process
The Committee of Creditors (CoC) of Cian Healthcare Limited has approved DMKH & Co. as the Transaction Auditor for the company's Corporate Insolvency Resolution Process (CIRP). The appointment covers the period from June 11, 2022, to August 14, 2024, with a remuneration of INR 195,000.00 plus taxes and expenses. The decision was made through an e-voting process with a 73.86% approval rate. Additionally, the CoC reduced the notice period for future meetings from 4 days to 2 working days.
06Aug 25
Cian Healthcare's Insolvency Resolution Plan Advances to NCLT Hearing on August 22, 2025
Cian Healthcare, undergoing Corporate Insolvency Resolution Process (CIRP), has its approved resolution plan scheduled for a hearing before the NCLT Mumbai Bench on August 22, 2025. The plan was approved by the Committee of Creditors on May 9, 2025, and submitted to NCLT on May 23, 2025. The company continues to comply with SEBI regulations by providing timely updates on the CIRP proceedings.
05Aug 25
Cian Healthcare's Insolvency Resolution Plan Hearing Scheduled for August 6, 2025
Cian Healthcare Limited, under insolvency proceedings, announced that the National Company Law Tribunal (NCLT) will consider the approval of its resolution plan on August 6, 2025. The plan, approved by the Committee of Creditors on May 9, 2025, was submitted to NCLT on May 23, 2025. Resolution Professional Roshen Chordiya confirmed these developments in a regulatory filing, emphasizing the company's commitment to transparency and compliance with SEBI regulations.
Cian Healthcare
4.90
-0.09
(-1.80%)
1 Year Returns:+49.85%
Industry Peers
Sun Pharmaceutical
1,700.70
(-1.62%)
Divis Laboratories
6,355.50
(-1.26%)
Torrent Pharmaceuticals
4,003.70
(+1.61%)
Cipla
1,434.50
(-0.95%)
Lupin
2,195.90
(+0.78%)
Dr Reddys Laboratories
1,186.50
(-0.40%)
Mankind Pharma
2,244.40
(+1.38%)
Zydus Life Science
883.75
(-1.88%)
Alkem Laboratories
5,830.50
(-0.56%)
Aurobindo Pharma
1,180.10
(+1.06%)